PMGC Holdings Inc

Research PMGC Holdings Inc (ELAB) on Bullrun: market cap USD 25.85M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 25.85M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 590.08K-USD 7.75M-USD 6.38M31.4%-784.83USD 5.40MUSD 2.64MUSD 7.84M
FY2024-USD 1.75M-USD 6.25M-USD 5.50Mn/a-1897.51USD 3.98MUSD 0USD 6.66M
FY2023USD 1.71M-USD 4.30M-USD 4.57M66.2%-0.4USD 3.33MUSD 210.49KUSD 3.83M
FY2022USD 766.28K-USD 1.80Mn/a58.4%-0.19USD 1.15Mn/aUSD 1.13M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 25.85Mn/an/an/a
20252025-12-31USD 2.87Mn/an/an/a
20242024-12-31USD 7.02Mn/an/an/a
20232023-12-29USD 21.55Mn/an/an/a

About PMGC Holdings Inc

PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is PMGC Holdings Inc's market cap?

PMGC Holdings Inc's market capitalization is USD 25.85M.

What does PMGC Holdings Inc do?

PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining. The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.